|Bid||0.01 x 1200|
|Ask||4.75 x 1300|
|Day's Range||4.10 - 4.17|
|52 Week Range||3.05 - 7.60|
|Beta (3Y Monthly)||-0.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage.
HOUSTON, Nov. 01, 2018 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected.
Every investor in PLx Pharma Inc (NASDAQ:PLXP) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
HOUSTON, Sept. 10, 2018-- PLx Pharma Inc., a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg, announced today ...
Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). ...
PLx Pharma Inc (NASDAQ:PLXP) is a small-cap stock with a market capitalization of USD $59.68M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...